Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc.HEPA · Entity 8208 | Director | May 18, 2021 | May 20, 2021 |
| RespireRx Pharmaceuticals Inc.RSPI · Entity 146118 | Director · Exec. Chairman & CSO | September 30, 2020 | October 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hepion Pharmaceuticals, Inc.
Report date May 18, 2021 · Filed May 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2031-05-18 | Direct | 291,110 |
Reported balance
After 2021-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-18 · Grant · Acquired 200,000 · Balance 291,110 F1: Stock Options have been granted subject to stockholder approval of an increase in the shares of common stock issuable pursuant to the 2013 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock Options have been granted subject to stockholder approval of an increase in the shares of common stock issuable pursuant to the 2013 Equity Incentive Plan.
RespireRx Pharmaceuticals Inc.
Report date September 30, 2020 · Filed October 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series H Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2023-09-30 | Direct | 100 |
Reported balance
After 2020-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-30 · Other · Acquired 100 · Balance 100 F1: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F2: On September 30, 2020, Dr. Lippa agreed to forgive a portion of accrued compensation owing from RespireRx Pharmaceuticals Inc. (the "Company") equal to $100,000, and in exchange, the Company issued to Dr. Lippa 100 shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock, which equates to a per share value of $1,000.00 per share. F3: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). |
| Series H Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2023-09-30 | Direct | 0 |
Reported balance
After 2020-09-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-30 · Gift · Disposed 100 · Balance 0 F1: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F4: The disposition or acquisition, as applicable, reflects an estate planning transaction. F3: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). |
| Series H Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2023-09-30 | IndirectBy Trust | 0 |
Reported balance
After 2020-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-09-30 · Gift · Acquired 100 · Balance 0 F1: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F4: The disposition or acquisition, as applicable, reflects an estate planning transaction. F3: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). F5: Dr. Lippa gifted these securities into a family trust for the benefit of his spouse, daughter and grandchildren. Dr. Lippa is not the trustee, does not exercise voting or investment control over shares held in the trust, and disclaims beneficial ownership of the shares of Series H Preferred Stock owned by the trust, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock".
F2: On September 30, 2020, Dr. Lippa agreed to forgive a portion of accrued compensation owing from RespireRx Pharmaceuticals Inc. (the "Company") equal to $100,000, and in exchange, the Company issued to Dr. Lippa 100 shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock, which equates to a per share value of $1,000.00 per share.
F3: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023).
F4: The disposition or acquisition, as applicable, reflects an estate planning transaction.
F5: Dr. Lippa gifted these securities into a family trust for the benefit of his spouse, daughter and grandchildren. Dr. Lippa is not the trustee, does not exercise voting or investment control over shares held in the trust, and disclaims beneficial ownership of the shares of Series H Preferred Stock owned by the trust, except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2021 Filed May 20, 2021 19:12 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001104659-21-070074 · tm2117144-7_4seq1.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,110 Underlying: Common Stock · 200,000 shares Expires 2031-05-18 F1 · security: Stock Options have been granted subject to stockholder approval of an increase in the shares of common stock issuable pursuant to the 2013 Equity Incentive Plan. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 15:47 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GiftSeries H Preferred Stock · Derivative | 100 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001493152-20-018819 · ownership.xml · derivative · entry 3 Lippa Arnold · CIK 0001363763 · Director · Exec. Chairman & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Conversion Units · 15,625,000 shares Expires 2023-09-30 F1 · security: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F4 · kind: The disposition or acquisition, as applicable, reflects an estate planning transaction. F3 · derivative.underlying: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). F5 · ownership.nature: Dr. Lippa gifted these securities into a family trust for the benefit of his spouse, daughter and grandchildren. Dr. Lippa is not the trustee, does not exercise voting or investment control over shares held in the trust, and disclaims beneficial ownership of the shares of Series H Preferred Stock owned by the trust, except to the extent of his pecuniary interest therein. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 15:47 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GiftSeries H Preferred Stock · Derivative | 100 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001493152-20-018819 · ownership.xml · derivative · entry 2 Lippa Arnold · CIK 0001363763 · Director · Exec. Chairman & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Conversion Units · 15,625,000 shares Expires 2023-09-30 F1 · security: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F4 · kind: The disposition or acquisition, as applicable, reflects an estate planning transaction. F3 · derivative.underlying: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 15:47 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | OtherSeries H Preferred Stock · Derivative | 100 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001493152-20-018819 · ownership.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director · Exec. Chairman & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Underlying: Conversion Units · 15,625,000 shares Expires 2023-09-30 F1 · security: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F2 · kind: On September 30, 2020, Dr. Lippa agreed to forgive a portion of accrued compensation owing from RespireRx Pharmaceuticals Inc. (the "Company") equal to $100,000, and in exchange, the Company issued to Dr. Lippa 100 shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock, which equates to a per share value of $1,000.00 per share. F2 · price: On September 30, 2020, Dr. Lippa agreed to forgive a portion of accrued compensation owing from RespireRx Pharmaceuticals Inc. (the "Company") equal to $100,000, and in exchange, the Company issued to Dr. Lippa 100 shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock, which equates to a per share value of $1,000.00 per share. F3 · derivative.underlying: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 16:17 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 30,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001104659-20-097600 · a4.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,110 Underlying: Common Stock · 30,000 shares Expires 2030-08-19 Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 21:14 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GiftSeries H Preferred Stock · Derivative | 600 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001493152-20-013399 · ownership.xml · derivative · entry 3 Lippa Arnold · CIK 0001363763 · Director · Exec. Chairman, CEO & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Conversion Units · 93,750,000 shares Expires 2023-09-30 F1 · security: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F4 · kind: The disposition or acquisition, as applicable, reflects an estate planning transaction. F3 · derivative.underlying: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). F5 · ownership.nature: Dr. Lippa gifted these securities into a family trust for the benefit of his spouse, daughter and grandchildren. Dr. Lippa is not the trustee, does not exercise voting or investment control over shares held in the trust, and disclaims beneficial ownership of the shares of Series H Preferred Stock owned by the trust, except to the extent of his pecuniary interest therein. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 21:14 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GiftSeries H Preferred Stock · Derivative | 600 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001493152-20-013399 · ownership.xml · derivative · entry 2 Lippa Arnold · CIK 0001363763 · Director · Exec. Chairman, CEO & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Conversion Units · 93,750,000 shares Expires 2023-09-30 F1 · security: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F4 · kind: The disposition or acquisition, as applicable, reflects an estate planning transaction. F3 · derivative.underlying: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 21:14 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | OtherSeries H Preferred Stock · Derivative | 600 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001493152-20-013399 · ownership.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director · Exec. Chairman, CEO & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Conversion Units · 93,750,000 shares Expires 2023-09-30 F1 · security: The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". F2 · kind: On July 13, 2020, Dr. Lippa agreed to forgive a portion of the accrued but unpaid compensation to which he was entitled pursuant to his employment agreement with RespireRx Pharmaceuticals Inc. (the "Company") equal to $600,000. On July 13, 2020, the Company issued to Dr. Lippa 600 shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock ("Series H Preferred Stock") in exchange for the forgiveness of $600,000 of accrued and unpaid compensation, which equates to a per share value of $1,000.00 per share. F2 · price: On July 13, 2020, Dr. Lippa agreed to forgive a portion of the accrued but unpaid compensation to which he was entitled pursuant to his employment agreement with RespireRx Pharmaceuticals Inc. (the "Company") equal to $600,000. On July 13, 2020, the Company issued to Dr. Lippa 600 shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock ("Series H Preferred Stock") in exchange for the forgiveness of $600,000 of accrued and unpaid compensation, which equates to a per share value of $1,000.00 per share. F3 · derivative.underlying: Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 16:14 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 60,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001104659-20-044173 · a4.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,109 Underlying: Common Stock · 60,000 shares Expires 2030-04-03 Read SEC document |
| March 22, 2020 Filed Mar 24, 2020 16:20 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GiftCommon Stock | 4,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001363763-20-000001 · primary_doc.xml · nonDerivative · entry 2 Lippa Arnold · CIK 0001363763 · Director · Exec. Chairman, CEO, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598 F2 · kind: Dr. Lippa gifted these securities into a family trust for estate planning purposes. He is not the trustee and does not exercise voting or investment control over shares held in the trust, but he is a beneficiary of the trust. Read SEC document |
| March 22, 2020 Filed Mar 24, 2020 16:20 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | OtherCommon Stock | 4,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001363763-20-000001 · primary_doc.xml · nonDerivative · entry 1 Lippa Arnold · CIK 0001363763 · Director · Exec. Chairman, CEO, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500,598 F1 · kind: On March 21, 2020, Dr. Lippa agreed to forgive a portion of the accrued but unpaid compensation to which he was entitled pursuant to his employment agreement with RespireRx Pharmaceuticals Inc. (the "Company") equal to $153,000. On March 22, 2020, the Company issued to Dr. Lippa 4,500,000 shares of the Company's common stock, in exchange for the forgiveness of $153,000 of accrued and unpaid compensation, which equates to a per share value of $0.034 per share, the closing share price of the Company's common stock on Friday, March 20, the last business day prior to the transaction. F1 · price: On March 21, 2020, Dr. Lippa agreed to forgive a portion of the accrued but unpaid compensation to which he was entitled pursuant to his employment agreement with RespireRx Pharmaceuticals Inc. (the "Company") equal to $153,000. On March 22, 2020, the Company issued to Dr. Lippa 4,500,000 shares of the Company's common stock, in exchange for the forgiveness of $153,000 of accrued and unpaid compensation, which equates to a per share value of $0.034 per share, the closing share price of the Company's common stock on Friday, March 20, the last business day prior to the transaction. Read SEC document |
| July 24, 2019 Filed Jul 25, 2019 16:15 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 970 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001104659-19-041843 · a4.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,109 Underlying: Common Stock · 970 shares Expires 2029-07-24 Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 17:56 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GiftCommon stock Warrants (right to buy) · Derivative | 47,620 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001363763-18-000001 · primary_doc.xml · derivative · entry 4 Lippa Arnold · CIK 0001363763 · Director · Exec Chairman, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,620 shares Expires 2023-04-30 F2 · kind: Dr. Lippa gifted these securities into a family trust for estate planning purposes. He is not the trustee and does not exercise voting control over shares held in the trust but he is a beneficiary of the trust. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 17:56 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 47,620 | Not disclosed Strike: $1.58 | Not disclosed |
DisclosureSEC source: 0001363763-18-000001 · primary_doc.xml · derivative · entry 3 Lippa Arnold · CIK 0001363763 · Director · Exec Chairman, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,620 Underlying: Common Stock · 47,620 shares Expires 2023-04-30 F1 · price: On April 5, 2018, the Company issued a promissory note to Dr. Lippa in the principal amount of $50,000. On September 12, 2018, the Company redeemed the note, and Dr. Lippa used $50,000 in redemption proceeds to acquire 47,620 units, each unit comprising 47,620 shares of Common Stock and 47,620 Warrants, each Warrant representing the right to purchase an additional share of Common Stock. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 17:56 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GiftCommon stock | 47,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001363763-18-000001 · primary_doc.xml · nonDerivative · entry 2 Lippa Arnold · CIK 0001363763 · Director · Exec Chairman, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Dr. Lippa gifted these securities into a family trust for estate planning purposes. He is not the trustee and does not exercise voting control over shares held in the trust but he is a beneficiary of the trust. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 17:56 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | PurchaseCommon Stock | 47,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001363763-18-000001 · primary_doc.xml · nonDerivative · entry 1 Lippa Arnold · CIK 0001363763 · Director · Exec Chairman, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,620 F1 · price: On April 5, 2018, the Company issued a promissory note to Dr. Lippa in the principal amount of $50,000. On September 12, 2018, the Company redeemed the note, and Dr. Lippa used $50,000 in redemption proceeds to acquire 47,620 units, each unit comprising 47,620 shares of Common Stock and 47,620 Warrants, each Warrant representing the right to purchase an additional share of Common Stock. Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 14:16 UTC | Hepion Pharmaceuticals, Inc. CTRV · Entity 8208 | PurchaseWarrants · Derivative | 8,625 | $1,000.00 Strike: $1.55 | $8,625,000.00 |
DisclosureSEC source: 0001104659-18-043794 · a4.xml · derivative · entry 2 Lippa Arnold · CIK 0001363763 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Linda Lippa Family Trust of 2007 Disclosed balance after: 8,625 Underlying: Common Stock · 8,625 shares Expires 2023-07-03 F3 · price: Shares of Series C Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series C Convertible Preferred Stock and 575 Warrants Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 14:16 UTC | Hepion Pharmaceuticals, Inc. CTRV · Entity 8208 | PurchaseSeries C Convertible Preferred Stock · Derivative | 15 | $1,000.00 Strike: $1.55 | $15,000.00 |
DisclosureSEC source: 0001104659-18-043794 · a4.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Linda Lippa Family Trust of 2007 Disclosed balance after: 15 Underlying: Common Stock · 9,678 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $1.55. F3 · price: Shares of Series C Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series C Convertible Preferred Stock and 575 Warrants F2 · derivative.expiration_date: Shares of Series C Convertible Preferred Stock do not expire. Read SEC document |
| December 09, 2017 Filed Dec 12, 2017 19:23 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GiftCommon Stock Options (to purchase shares of Common Stock) · Derivative | 559,595 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001573202-17-000011 · primary_doc.xml · derivative · entry 2 Lippa Arnold · CIK 0001363763 · Director · Exec Chairman, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Commmon Stock · 559,595 shares Expires 2022-12-09 F2 · kind: Dr. Lippa gifted these Common Stock Options into a family trust for estate planning purposes. He is not the trustee and does not exercise voting or investment control over shares held in the trust but he is a beneficiary of the trust. F1 · derivative.exercise_date: On December 9, 2017, Dr. Lippa forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $807,497. On that date, the Company granted to Dr. Lippa options to purchase 559,595 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $807,497. These Common Stock Options vested upon issuance. Read SEC document |
| December 09, 2017 Filed Dec 12, 2017 19:23 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | OtherCommon Stock Options (to purchase shares of Common Stock) · Derivative | 559,595 | Not disclosed Strike: $1.45 | Not disclosed |
DisclosureSEC source: 0001573202-17-000011 · primary_doc.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director · Exec Chairman, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,595 Underlying: Commn Stock · 559,595 shares Expires 2022-12-09 F1 · kind: On December 9, 2017, Dr. Lippa forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $807,497. On that date, the Company granted to Dr. Lippa options to purchase 559,595 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $807,497. These Common Stock Options vested upon issuance. F1 · price: On December 9, 2017, Dr. Lippa forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $807,497. On that date, the Company granted to Dr. Lippa options to purchase 559,595 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $807,497. These Common Stock Options vested upon issuance. F1 · derivative.exercise_date: On December 9, 2017, Dr. Lippa forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $807,497. On that date, the Company granted to Dr. Lippa options to purchase 559,595 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $807,497. These Common Stock Options vested upon issuance. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:45 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | OtherCommon Stock Options (to purchase shares of Common Stock) · Derivative | 50,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001573202-17-000004 · primary_doc.xml · derivative · entry 2 Lippa Arnold · CIK 0001363763 · Director · Executive Chairman & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 50,000 shares Expires 2022-06-30 F2 · kind: Mr. Lippa transferred these Common Stock Options into a family trust for estate planning purposes. He is not the trustee and does not exercise voting or investment control over shares held in the trust but he is a beneficiary of the trust. F1 · derivative.exercise_date: These Common Stock Options vested upon issuance. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:45 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GrantCommon Stock Options (to purchase shares of Common Stock) · Derivative | 50,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001573202-17-000004 · primary_doc.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director · Executive Chairman & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: common stock · 50,000 shares Expires 2022-06-30 F1 · derivative.exercise_date: These Common Stock Options vested upon issuance. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:16 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | OtherCommon Stock Options (to purchase shares of Common Stock) · Derivative | 50,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001363763-17-000004 · primary_doc.xml · derivative · entry 2 Lippa Arnold · CIK 0001363763 · Director · Executive Chairman and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2017-01-18 F2 · kind: Mr. Lippa transferred these Common Stock Options into a family trust for estate planning purposes. He is not the trustee and does not exercise voting or investment control over shares held in the trust but he is a beneficiary of the trust. F1 · derivative.exercise_date: These Common Stock Options vest in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:16 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GrantCommon Stock Options (to purchase shares of Common Stock) · Derivative | 50,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001363763-17-000004 · primary_doc.xml · derivative · entry 1 Lippa Arnold · CIK 0001363763 · Director · Executive Chairman and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2022-01-18 F1 · derivative.exercise_date: These Common Stock Options vest in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.